News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Subscribe To Our Newsletter & Stay Updated
